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Abstract: Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancers, which are the 
leading cause of cancer-related deaths in the world. Tyrosine kinase inhibitors such as erlotinib represent one 
therapeutic options presently recommended for tumors produced by activating mutations in the gene coding of 
epidermal growth factor receptor (EGFR). The aim of this study is the identification of possible biomarkers for tumor 
sensitivity to erlotinib in the absence of the main EGFR mutations. The erlotinib sensitivity of cells isolated from 
41 untreated NSCLC patients was determined and compared with the presence of the more frequent EGFR muta-
tions. Several patients had tumor cells highly sensitive to erlitinib in the absence of the EGFR mutations analyzed. 
The gene expression profile of 3 erlotinib-sensitive tumors was compared with that of 4 resistant tumors by DNA 
microarray hybridization. Sixteen genes were expressed at significantly higher levels in the resistant tumors than in 
the sensitive tumors. The possible correlation between erlotinib sensitivity and the expression of these genes was 
further analyzed using the data for the NSCLC, breast cancer and colon cancer cell lines of the NCI60 collection. The 
expression of these genes was correlated with the overall survival of 5 patients treated with erlotinib, according to 
The Cancer Genome Atlas (TCGA) database. Overlapping groups of 7, 5 and 3 genes, including UGT1A6, TRIB3, MET, 
MMP7, COL17A1, LCN2 and PTPRZ1, whose expression correlated with erlotinib activity was identified. In particular, 
low MET expression levels showed the strongest correlation.
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Introduction
Lung cancer is the leading cause of cancer-
related mortality in the world [1], and non-small 
cell lung cancer (NSCLC) represents approxi-
mately 85% of the cases. Lung cancer treat-
ment is hampered by a lack of specific treat-
ments and by the frequent development of 
resistance to chemotherapy. There is an urgent 
need to determine the pathogenic and drug-
resistance mechanisms involved in NSCLC. 
Activation of the epidermal growth factor recep-
tor (EGFR) regulatory pathway is one of the 
mechanisms that result in NSCLC generation 
[2]. Inhibition of this pathway is considered a 
promising possibility for lung cancer treatment 
[3].
Several alterations result in EGFR pathway acti-
vation, including gene amplification, overex-
pression and mutation [4]. Constitutively acti-
vated proteins can derive from missense 
mutations or small deletions. Among the most 
frequent missense mutations is one changing 
leucine 585 into arginine; small in-frame dele-
tions in exon 19 of the genes are also frequent 
[5]. Two general approaches have been used to 
inhibit the EGFR pathway [4]. First is the use of 
antibodies that recognize the extracellular 
region of the receptor and avoid ligand binding 
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and/or receptor activation. Among the present-
ly used antibodies are cetuximab and necitu-
mumab. Second is the use of molecules that 
inhibit of the receptor’s tyrosine kinase activity, 
required for signal transduction. These mole-
cules are known as tyrosine kinase inhibitors 
(TKIs), among which are erlotinib (Tarceva®), 
gefitinib, lapatinib and canertinib [4].
Initial clinical trials of unclassified lung cancer 
patients indicated that the use of EGFR inhibi-
tors did not lead to any significant improvement 
of overall survival or disease-free interval. 
However, treatment of patients who presented 
EGFR overexpression or activating mutations 
resulted in a significant objective response and 
improved overall survival [6, 7]. The presence 
of EGFR mutations is currently considered the 
most important predictor of clinical response to 
treatment with TKIs [8]. Erlotinib has been also 
approved by the US Food and Drug 
Administration and the European Medicines 
Agency for treatment of all patients with 
advanced NSCLC in second- and third-line. 
However, its efficacy for these treatments is 
still contentious and some clinical trials indi-
cated that chemotherapy could be more effec-
tive for second-line treatment of previously 
treated NSCLC patients.
However, recent trials have shown that TKIs 
can also have activity against NSCLCs that do 
not present EGFR-activating mutations [9]. 
There is therefore a need to identify new rele-
vant biomarkers that would allow the selection 
of TKI-sensitive patients independently of the 
presence of EGFR mutations. In this study, the 
sensitivity to the TKI erlotinib [10] was deter-
mined in NSCLC biopsies and compared with 
the presence of the more frequent EGFR muta-
tions. A population of tumors was identified 
that were highly sensitive to erlotinib in the con-
text of nonmutated EGFR. Comparative micro-
array analyses of gene expression allowed the 
identification of 16 genes that are underex-
pressed in sensitive tumors in comparison with 
erlotinib-resistant tumors. We propose that the 
expression of some of these genes could be a 
new biomarker of erlotinib sensitivity in NSCLC 
tumors.
Materials and methods
Processing of surgical samples
NSCLC samples were collected at La Paz 
University Hospital, Madrid (Spain), in DMEM/
MixF12 Ham medium (Sigma, St. Louis, MO, 
USA). They were incubated with collagenase 
(0.3 mg/mL) and hyaluronidase (125 U/mL) 
(both from Sigma) at 37°C for 20 min, mechani-
cally disaggregated and filtered [11].
Cell viability assays
Disaggregated cells were cultured in 96-well 
plates at a density of 50 cells/well. After 24 h 
of culture, various concentrations of erlotinib 
(Tarceva®, F. Hoffmann-La Roche Ltd, Basel, 
Switzerland) were added, and the culture 
continued for 72 h. Cell viability was esti- 
mated by MTS (3-[4,5-dimethylthiazol-2-yl]-
5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-
2H-tetrazolium) hydrolysis (Promega, Madison, 
WI, USA). The assays were performed in 
triplicate. 
RNA and DNA isolation
RNA was extracted from surgical samples fro-
zen in optimal cutting temperature (OCT) (Miles, 
Elkhart, IN, USA) using the TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA) and purified 
with the RNeasy Mini Kit (Qiagen, Valencia, CA, 
USA). DNA was extracted from paraffin sections 
treated with xylene. The samples were incubat-
ed in 20 mM EDTA, 65 mM NaCl, 1% SDS and 
0.5 µg/mL of proteinase K (Sigma, St. Louis, 
MO, USA) for 12-16 h at 37°C. DNA was extract-
ed using phenol/chloroform/isoamyl alcohol 
(25:24:1) and precipitated with ethanol. 
EGFR mutation detection
Detection of the EGFR exons 20 and 21 muta-
tions was performed by allelic discrimination 
using quantitative PCR [12]. Oligonucleotides 
5’-AGGCAGCCGAAGGGCA-3’, 5’-CCTCACCTCCA- 
CCGTGCA-3’, FAM-labeled 5’-TGAGCTGCATGAT- 
GA-3’ and VIC-labeled 5’-TGAGCTGCGTGATGA 
-3’ were used for discrimination of the exon 
20 T790M mutation. Oligonucleotides 5’-AAC- 
ACCGCAGCATGTCAAGA-3’, 5’-TTCTCTTCCGCAC- 
CCAGC-3’, FAM-labeled 5’-CAGATTTTGGGCGG- 
GCCAAAC-3’ and VIC-labeled 5’-TCACAGATTT- 
TGGGCTGGCCAAAC-3’ were used for detection 
of the exon 21 L858R mutation. Exon 21 
was amplified by PCR before variant analysis 
using the oligonucleotides 5’-CTAACGTTCG- 
CCAGCCATAAGTCC-3’ and 5’-GCTGCGAGCTCA- 
CCCAGAATGTCTGG-3’. The PCR products 
were analyzed using the StepOnePlus Real-
Time PCR System (Life Technologies, Applied 
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Biosystems, Carlsbad, CA, USA). Exon 19 muta-
tions were detected by DNA sequencing after 
amplification of the exon using 
the oligonucleotides 5’-GTGATC- 
GCTGGTAACATCC-3’ and 5’-CAT- 
AGAAAGTGAACATTTAGGATGT- 
G-3’. Oligonucleotides were ob- 
tained from Applied Biosystems 
and Sigma. 
DNA microarray hybridization 
and analysis of the results
Total RNA (200 ng) was ampli- 
fied using the one-color Low In- 
put Quick Amp Labeling Kit 
(Agilent Technologies) and puri-
fied using the RNeasy Mini Kit 
(Qiagen). The labeled probes 
were hybridized to Whole Human 
Genome Microarrays 4x44K 
G4112F (Agilent). Hybridization, 
data extraction and analysis of 
the data were performed at the 
CNB (National Biotechnology 
Center, Madrid, Spain). Diffe- 
rential expression was deter-
mined using the rank product 
method [13]. Data were filtered 
and visualized as previously 
described [14]. Genes with an 
FDR lower than 0.1 were con- 
sidered as differentially ex- 
pressed. The GOTree Machine 
(GOTM) [15] was used to analyze 
functional enrichment in the 
selected genes.
Reverse transcription and quanti-
tative PCR
One microgram of RNA was 
converted into cDNA using a 
High Capacity RNA-to-cDNA kit 
(Applied Biosystems). Quanti- 
tative PCR amplification was per-
formed using TaqMan probes and 
the HT7900 platform (Applied 
Biosystems). The TaqMan probes 
used were: Hs03929097_g1 
(GAPDH), Hs00899658_m1 (MM- 
P1), Hs00950669_m1 (AREG) 
and Hs01565584_m1 (MET). 
Relative gene expression was cal-
Table 1. General characteristics of the patients analyzed in the 
study
Patient Age Sex Smoker Histologya Stage Genotype Sensitivityb
1 74 M No AdCa III WT 90
2 57 F - EpCa III WT 90
3 70 F No AdCa III WT 100
4 65 F - Other - WT 100
5 53 F - EpCa - WT 100
6 72 F - EpCa III WT 90
7 44 M Yes Other I WT 70
8 86 F - EpCa I WT 90
9 52 F Ex AdCa III WT 100
10 61 F Yes AdCa I WT 100
11 77 F Yes Other I WT 100
12 75 F - LCCa I WT 100
13 66 F Ex EpCa III WT 100
14 61 F - Other I WT 40
15 72 F - LCCa I WT 100
16 77 F No AdCa I WT 100
17 81 F - AdCa I WT 90
18 62 F - EpCa I WT 70
19 46 F Ex EpCa II WT 100
20 52 F Ex AdCa I WT 80
21 48 M Ex AdCa III WT 60
22 68 F Ex EpCa III WT 100
23 72 F Yes EpCa I WT 100
24 67 F Yes AdCa II WT 60
25 80 F No EpCa I WT 100
26 62 F No EpCa III WT 70
27 84 F No EpCa II WT 50
28 45 F Ex AdCa III WT 70
29 67 M Ex Other I Mut_Ex19 60
30 75 F - EpCa - WT 30
31 60 F Yes EpCa III Mut_Ex19 70
32 61 F Yes EpCa III WT 30
33 47 M Yes EpCa I WT 60
34 49 F Ex AdCa II WT 100
35 64 M Yes AdCa I WT 40
36 60 F Yes EpCa III WT 60
37 59 M No AdCa I WT 30
38 66 F - Other I WT 50
39 67 F No AdCa II WT 100
40 63 F Yes EpCa II WT 60
41 60 F Yes EpCa I WT 0
aAdCa: adenocarcinoma; EpCa: epidermoid carcinoma; LCCa: large-cell carcino-
ma. bPercentage of cell viability after 24 hours of treatment with 10 µM erlotinib.
culated by the threshold cycle method [16] 
using GAPDH as endogenous control.
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Results
Erlotinib sensitivity of cells isolated from 
NSCLC patients 
Surgical samples of 41 patients with NSCLC 
at stages I-III were collected at La Paz Uni- 
versity Hospital (Madrid, Spain). Patient history, 
histological classification and stage of the 
tumors are shown in Table 1. Cells were isolat-
ed from each surgical sample and their sensi-
tivity to erlotinib (Tarceva®) determined. The 
results are summarized in the right column of 
Table 1 that shows cell viability to a 10 µM con-
centration of erlotinib. DNA was extracted from 
each surgical sample and the presence of the 
more frequent EGFR activating mutations, 
small in-frame deletions in exon 19 of the gene 
and missense mutations in exon 21 (L858R) 
[5] and the more frequent mutation confering 
erlotinib resistance (exon 20, T790M [17]) were 
determined. Only two of the samples included 
small deletions in exon 19 (patients 29 and 31 
in Table 1), the mutations most frequently 
found in the Spanish population [5]. These two 
samples were sensitive to erlotinib (60%-70% 
cell viability at 10 µM erlotinib, Table 1). 21 of 
the samples that did not have the studied 
mutations were resistant to erlotinib (more 
than 90% cell viability). The rest of them were 
sensitive, and a significant number (8) were 
very sensitive to the drug (less than 50% cell 
viability).
Gene expression profile
Since the patient samples that were more sen-
sitive to erlotinib did not present the more fre-
quent EGFR mutations, the gene expression 
profile of sensitive samples was compared with 
that of resistant ones to get information on the 
biological bases of their sensitivity. Thus, RNA 
was obtained from 4 resistant (15, 16, 17 and 
19) and 3 sensitive samples (32, 35 and 38), 
converted to cDNA and hybridized to DNA 
microarrays containing 44,000 human gene 
probes. Sixteen genes were identified that were 
over-expressed in the resistant samples com-
pared with the sensitive ones, considering a 
false discovery rate of less than 0.1 (Table 2). 
Gene ontology analyses indicated a significant 
enrichment in gene coding for proteins 
expressed in the extracellular region (9 genes, 
P = 8.19 × 10-5), involved in the formation of 
the extracellular matrix (4 genes, P = 0.0009), 
in collagen catabolic processes (2 genes, P = 
0.0059) and in components of the basal plas-
ma membrane (2 genes, P = 0.0009).
The expression of 3 of the genes identified was 
further analyzed by quantitative RT-PCR. The 7 
samples used for the microarray were tested, 
as well as 2 additional samples sensitive to 
erlotinib but not highly sensitive (Figure 1). The 
analyzed samples showed a broad variation in 
expression levels; however, the average expres-
sion in the resistant, sensitive and highly sensi-
Table 2. Summary of the genes identified in the DNA Microarray analyses
Gene Accession number Description Exp. Difference
LCN2 NM_005564 Lipocalin 2 -9.12
IGF2 NM_00100713 Insulin-like growth factor 2 -7.88
UGT1A6 NM_001072 UDP glucuronosyltransferase 1 family -7.87
MMP1 NM_002421 Matrix metallopeptidase 1 -7.36
COL17A1 NM_000494 Collagen 17 -6.94
PIGR NM_002644 Polymeric immunoglobulin receptor -6.77
AREG NM_001657 Amphiregulin -6.58
IGHG4 ENST00000379913 IgA1-A2 lambda hybrid -6.57
PTPRZ1 NM_002851 Protein tyrosine phosphatase; pleiotrophin receptor -6.5
AKR1C3 NM_003739/ Aldo-keto reductase family 1 -6.4
MMP7 NM_002423 Matrix metallopeptidase 7 -6.37
S100A2 NM_005978 S100 Ca-binding protein A2 -6.33
MET NM_000245 Oncogene MET -5.92
SAA1 NM_000331 Serum amyloid A1 -5.81
C4BPA NM_000715 Complement component 4 binding protein -5.47
TRIB3 NM_021158 Tribbles homolog 3 -4.94
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tive samples (shown under the graphs in Figure 
1) was in agreement with the data obtained in 
the microarray analyses. The highly sensitive 
samples expressed lower levels of the 3 genes 
while samples with intermediate sensitivity 
expressed lower levels of MET, but similar lev-
els of MMP1 and AREG mRNAs than the resis-
tant samples.
Comparative analyses in NCI60 cancer cell 
lines
To further test if the expression of these 16 
genes was related to erlotinib sensitivity we 
analyzed their expression in the NCI60 series 
of cancer cell lines. These cell lines have been 
broadly used for functional and pharmacologi-
cal studies. Their genotype and gene expres-
sion profiles have been determined [18] and 
are publicly available through the NCI60 data-
base (http://discover.nci.nih.gov/cellminer). We 
focused the study on the 21 NCI60 cell lines 
derived from tumors typically treated with erlo-
tinib (breast cancer, colon cancer and NSCLC). 
In this database, erlotinib response is 
expressed as the negative logarithm of the 
IC50 molar concentration, thus increasing with 
the sensitivity of the sample. Since the genes 
identified have lower expression in more sensi-
tive cells, a negative correlation between gene 
expression and erlotinib response was expect-
ed. Seven of the 16 genes showed a significant 
negative correlation (correlation coefficient, R, 
lower than -0.3), excluding the NSCLC EKVX 
and H322M cell lines, as will be discussed in 
Section 4. Because a wide variability in the 
expression of each gene had been observed in 
the patient samples (Figure 1), we considered 
that the average expression of the genes could 
be more relevant than the expression of each 
Figure 1. Analyses of gene expression by reverse 
transcription and quantitative PCR. RNA was iso-
lated from frozen sections of the NSCLC biopsies 
corresponding to 4 patients whose cells were not 
sensitive to erlotinib (white bars corresponding to 
patients 15, 16, 17 and 19 in Table 1), sensitive 
(gray bars, patients 21 and 26) or highly-sensitive 
(black bars, patients 32, 35 and 38). The RNAs 
were converted to cDNA and the relative expression 
levels of MMP1 (upper left panel), AREG (upper right 
panel) and MET (lower panel) were determined by 
quantitative PCR. The average relative expression 
levels of the resistant, sensitive and highly sensitive 
samples are indicated under each group of bars.
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MMP7 and COL17A1. A correlation coefficient 
of -0.328 was observed considering the aver-
age expression of these 5 genes (Figure 2B). 
When the analyses were further focused on the 
individually. The correlation observed with the 
average expression of these 7 genes: LCN2, 
MET, MMP7, PTPRZ1, TRIB3, UGT1A6 and 
COL17A1; is shown in Figure 2A, solid line (R = 
-0.27). Omitting the NSCLC 
cell lines EKVX and H322M 
(the 2 samples to the right in 
Figure 2A) the correlation 
coefficient was -0.615 (bro-
ken line in Figure 2A). If all 
cell lines are considered, 5 
genes showed a negative 
correlation between erlotinib 
response and gene expres-
sion: MET, TRIB3, UGT1A6, 
Figure 2. Correlation between gene expression levels and erlotinib activity in NSCLC, breast cancer and colon 
cancer NCI60 cell lines. Relative expression levels of the indicated genes in 9 NSCLC, 5 breast cancer and 7 
colon cancer cell lines, were obtained from the NCI60 database. The same source was used to determine the 
erlotinib activity in these cell lines, expressed as the negative logarithm of the IC50 concentration. The correlation 
between relative gene expression levels (Y-axis) and erlotinib activity (X-axis) is represented for each cell line. A. 
Correlation of the average relative expression levels of the genes UGT1A6, TRIB3, MET, MMP7, COL17A1, LCN2 and 
PTPRZ1 and erlotinib activity for each cell line. The solid line indicates the correlation found considering all the cell 
lines (R = -0.265), whereas the broken line indicates the correlation obtained excluding the two cell lines shown at 
the right of the graph (NSCLC cell lines EKVX and H322M; R=-0.615). B. Correlation of the average relative expres-
sion level of the genes UGT1A6, TRIB3, MET, MMP7 and COL17A1 and erlotinib activity. The solid line indicates the 
correlation found for all the cell lines (R=-0.328). C. Correlation of the average relative expression level of the genes 
UGT1A6, TRIB3 and MET and erlotinib activity. The solid line indicates the correlation found for all the cell lines (R 
= -0.529).
Table 3. Clinical history of the analyzed TCGA patients with NSCLC 
Barcode patient Sex Histological type Stage Smoker Days to death
TCGA-05-4402 F Adenocarcinoma IV No 244
TCGA-22-5480 F Squamous cell carcinoma IA Yes 2170
TCGA-53-7624 F Adenocarcinoma IV Yes 1043
TCGA-60-2715 M Squamous cell carcinoma IA Yes 1075
TCGA-62-A46S M Papillary adenocarcinoma IB Yes 1653
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3 genes that showed a correlation coefficient 
less than -0.3 (MET, TRIB3 and UGT1A6), their 
average expression gave a correlation coeffi-
cient of -0.529 (Figure 2C).
Comparative analyses at the cancer genome 
atlas database
The Cancer Genome Atlas (TCGA) database 
(http://cancergenome.nih.gov/) is a collabora-
tive project that catalogues genomic data for 
over 20 types of cancer. This database con-
tains information concerning 5 patients with 
lung adenocarcinoma and squamous cell lung 
carcinoma treated with erlotinib, (Table 3). The 
gene expression data from these patients, 
obtained in RNA-Seq experiments [19, 20], 
were correlated with their survival after erlo-
tinib treatment (Figure 3). Considering the 7 
genes selected using the NCI60 cell lines, the 
strongest correlation was between MET expres-
sion and overall patient survival (R = -0.783) 
(Figure 3A). The average expression of the 3 
genes characterized in Section 3.3 (MET, 
TRIB3, UGT1A6) also demonstrated a signifi-
cant correlation (R = -0.445) (Figure 3B). When 
the average expression of the 5 genes 
described above was compared (Figure 3C), 
the correlation coefficient decreased to -0.181, 
due to the high expression levels of the 
COL17A1 gene in one of the patients. When the 
group of 7 genes was considered, the correla-
tion coefficient was -0.206.
Discussion
The sensitivity to erlotinib of cells isolated from 
41 NSCLC surgical samples from patients who 
had not received any previous treatment was 
determined. Because activating EGFR muta-
tions are considered the most useful predictive 
marker of erlotinib response [8, 21-23], the 
presence of the more common mutations was 
tested. Two of the patients presented small 
deletions in EGFR exon 19, and their cells were 
sensitive to erlotinib, as expected. However, 
cells from 8 patients who did not present the 
studied mutations were even more sensitive to 
erlotinib. These patients did not show any dis-
tinctive differences in sex, histology, tumor 
grade or smoking habits. Their cells could pres-
ent other non-analyzed EGFR mutations, given 
that an increasing number of mutations are 
being described [2]; however, the relatively high 
number of sensitive samples makes this possi-
bility unlikely because these other mutations 
Figure 3. Correlation between gene expression levels 
and overall survival of erlotinib treated patients. The 
gene expression levels of 5 patients with NSCLC treated 
with erlotinib were downloaded from The Cancer Ge-
nome Atlas (TCGA) database. The expression level of 
each gene was normalized to the average expression of 
the gene in the 5 patients and the relative expression is 
indicated in the Y-axis. The survival of each patient af-
ter erlotinib treatment is presented at the X-axis in days. 
Panel A represents the correlation found for MET gene 
expression, with a correlation coefficient (R) of -0.783. 
Panel B shows the correlation found for the average rela-
tive expression of the genes MET, TRIB3 and UGT1A6 
(R = -0.445). Panel C shows the correlation found for 
the average relative expression of the genes MET, TRIB3, 
UGT1A6, MMP7 and COL17A1 (R = -0.181).
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are present in a low proportion of NSCLC 
patients. In agreement with this observation, 
Jazieh et al. [9] recently described patients who 
respond to tyrosine kinase inhibitors who do 
not present EGFR mutations.
The identification of patients who respond to 
erlotinib in the absence of EFGR mutations 
could be of great therapeutic interest. 
Therefore, the gene expression profiles of sen-
sitive and resistant patients were compared to 
find possible markers of the EFGR-non-mutated 
erlotinib-sensitive patients. Sixteen genes 
expressed at lower levels in sensitive samples 
were found. Many of them are involved in can-
cer-related processes. Among them, the 
expression of MMP1 [24], MMP7 [25], SAA1 
[26], S100A2 [27] and AKR1C3 [28] was relat-
ed to cell invasion and cancer metastasis. PIGR 
[29], TRIB3 [30], LCN2 [31] and IGF2 [32] 
expression was related to cell proliferation. 
PTPRZ1 [33], AREG (EGFR ligand [34]), TRIB3 
[30] and MET [35] proteins participate in cell 
signaling pathways related to cancer. In addi-
tion, UGT1A6 [36], C4BP [37], AREG [38] and 
LCN2 [39] expression has been related to 
NSCLC cell response to chemotherapy and 
radiotherapy. In general terms, the lower 
expression of these genes would predict lower 
invasive and metastatic capacity, increased 
sensitivity to chemotherapy and increased pro-
liferative capacity of the more sensitive patient 
cells. At least 3 of the proteins encoded by 
these genes, C4BP [40], IGF2 [41] and SAA1 
[26], are present in serum and could easily be 
detected and quantified.
The results obtained using patient cells were 
further tested on the NCI60 group of cancer 
cell lines. The analysis was focused on the can-
cer types that receive erlotinib treatment 
(breast cancer, colon cancer and NSCLC). The 
average expression of a group of 7 genes iden-
tified in our analyses showed correlation with 
erlotinib sensitivity (R = -0.265). The correla-
tion coefficient increased to -0.615 if the 
NSCLC cell lines EKVX and H322M were exclud-
ed from the analyses. These two cell lines are 
highly sensitive to erlotinib and express aver-
age levels of the 7 genes analyzed. However, 
the EFGR gene is not mutated or overexpressed 
in these two cell lines, and were included in 
subsequent analyses. The correlation coeffi-
cient increased when the expression of the 5 (R 
= -0.328) or 3 (R = -0.529) more related genes 
was considered. These results are therefore in 
good agreement with the results obtained from 
the patient cells. 
The 3 genes showing the strongest correlation 
with erlotinib sensitivity are UGT1A6, TRIB3 
and MET. UGT1A6 codes for a UDP glucuronos-
yltransferase with detoxifying activity and 
increased expression could result in erlotinib 
modification and degradation or decreased 
activity of the drug. Polymorphisms in this gene 
have been previously associated with lung can-
cer [42]. TRIB3-encoded protein activates the 
Notch signaling pathway, and upregulation of 
this gene in patients with NSCLC has been 
related to increased metastasis and poor prog-
noses [43]. MET codes for the hepatocyte 
growth factor receptor [44]. MET is considered 
as an oncogene because it is mutated in an 
increasing proportion of patients with NSCLC 
[2]. In addition, MET amplification is one of the 
mechanisms that induces resistance to erlo-
tinib and other TKI drugs [45, 46]. The data 
reported in this article are in agreement with 
these observations and would further indicate 
that low expression levels of MET could predict 
increased erlotinib sensitivity in NSCLC tumors.
The group of 5 genes also includes MMP7 and 
COL17A1. MMP7 codes for an extracellular 
metalloproteinase whose overexpression cor-
relates with NSCLC tumor proliferation and 
poor prognosis [47]. Polymorphisms in the pro-
moter region are associated with metastasis 
[24]. COL17A1 codes for the alpha subunit of 
type XVII collagen. This protein has not been 
previously related to cancer biology. The group 
of 7 genes also includes LCN2 and PTPRZ1. 
LCN2 codes for lipocalin 2, and high expression 
levels of this protein have been related to radio-
resistance [39]. PTPRZ1 codes for the pleiotro-
phin receptor and is considered oncogenic in 
small cell lung cancer [33]. 
The results obtained were further tested using 
the information available in the TCGA database 
on the gene expression profile and clinical his-
tory of cancer patients. The overall survival of 5 
NSCLC patients treated with erlotinib was com-
pared with the expression profile of the genes 
described above. A negative correlation was 
found between the expression of the groups of 
the 5 and 3 genes identified and the survival of 
the erlotinib-treated patients with correlation 
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coefficients of -0.181 and -0.445, respectively. 
However, the strongest correlation was found 
between MET expression and overall survival 
(R = -0.783). It is of interest that these data, 
obtained from the clinical treatment of patients, 
are in good agreement with the data obtained 
from cells isolated from untreated patients and 
in cancer cell lines.
In summary, this article identifies 16 genes 
whose expression appears to be related to erlo-
tinib sensitivity in patients with NSCLC who do 
not carry the more common EGFR mutations. 
This group can be further narrowed to 7, 5 or 3 
genes whose expression is more closely relat-
ed to erlotinib sensitivity in the NCI60 reper-
toire of the NSCLC, breast cancer and colon 
cancer cell lines. The analysis of the data 
available for 5 patients in the TCGA database 
was in agreement with these results, whereas 
the more significant association was found 
between MET expression and overall survival 
after erlotinib treatment. These observations 
would require confirmation in a larger cohort of 
patient samples to ascertain the clinical utility 
of the expression of these genes as a predic-
tive biomarker of erlotinib activity.
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